On November 9, Forbes China released its “2023 List of the 50 Most Innovative Companies”, and Imeik Technology Development Co., Ltd. proudly made the list—standing out as the only selected company from the consumer healthcare sector.
Imeik's inclusion is a result of its continuous innovation capabilities. From filling market gaps to leading the medical aesthetics sector, the company's long-standing R&D strength and accomplishments have once again been recognized.
The Forbes China’s “50 Most Innovative Companies” list is one of the brand’s signature rankings and has now been released for six consecutive years. This year’s evaluation criteria covered several dimensions: innovation capacity (including R&D investment and core proprietary intellectual property), corporate governance (digitalization and management quality), growth potential (key financial indicators over the past three years), innovation-driven market advantages (such as market share of core products and their substitutability), and overall social reputation. Other listed companies span various industries and include LONGi Green Energy, Advanced Micro-Fabrication Equipment Inc., Huawei, BeiGene, BYD, iFLYTEK, and Nongfu Spring.
Forbes China placed particular emphasis on R&D investment growth this year. Data shows that more than 80% of the listed companies significantly increased their R&D spending, with an average rise of over 6% compared to last year. This underscores a common trait among the top 50: building product R&D into the core of their development strategies to gain an edge in an uncertain global economy and highly competitive market landscape.
As one of the first companies in China to independently develop and apply biomedical materials for aesthetic medicine, Imeik continues to prioritize R&D innovation. Through in-house development and strategic partnerships, the company has laid out a comprehensive plan for the medical aesthetics industry—spanning products, technology, services, and ecosystem construction. Since its establishment, Imeik has consistently invested 7%–12% of its annual revenue in R&D. From 2018 to 2022, the compound annual growth rate (CAGR) of its R&D expenses reached an impressive 50.6%.
In recent years, the company has focused on refining its medical materials based on the specific needs of various facial and body tissue areas. It is also developing biopharmaceutical products such as recombinant proteins and peptides, expanding its product range from biomaterials into biopharmaceuticals and chemical medicines. While each product serves a unique function, they also exhibit strong synergies, enabling Imeik to meet the rapidly evolving and growing demands of Chinese consumers.
Being selected for the Forbes China’s “50 Most Innovative Companies” list affirms Imeik’s resilience and consistent growth in an uncertain environment, as well as its dual recognition from both the market and capital investors. As regulatory standards and industry policies in China’s medical aesthetics sector continue to mature, Imeik will further unleash its growth potential through continuous innovation in technology, products, and business models—delivering even better services to its broad consumer base.
